Why the study?
Preexisting capsid antibodies are prevalent in the population and pose a challenge to the safety and efficacy of AAV-mediated gene therapies.
Does exposure to AAV9 capsids activate complement in seropositive human donor sera?
Population
Sera from a cohort of human donors
Comparison
AAV9 capsid exposure with or without IgG-depletion or IgG degrading enzyme pretreatment
Authors
Loading...
May support IgG depletion to mitigate complement risk in seropositive AAV9 recipients; leaves open in vivo validation.
Does exposure to AAV9 capsids activate complement in seropositive human donor sera?
Preexisting neutralizing antibodies in human sera activate complement upon exposure to AAV9 capsids, highlighting an immune risk for AAV-mediated gene therapies that can be mitigated by IgG depletion.
West et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: